Table 4.
GSTT1, GSTM1, A313G GSTP1 and C341T GSTP1 in Relation to the Primary Sites of Head and Neck Cancer Tumors
| Oral cavity |
Larynx |
Pharynx |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 87 (44.0%) | n = 64 (32.0%) | n = 37 (19.0%) | |||||||
| n (%) | OR (95% CI) | p | n(%) | OR (95% CI) | p | n (%) | OR (95% CI) | p | |
| GSTM1 | |||||||||
| Positive | 43 (49.0) | Reference | 33 (51.0) | Reference | 19 (51.0) | Reference | |||
| Negative | 44 (51.0) | 0.98 (0.53-1.83) | 0.955 | 31 (49.0) | 1.02 (0.51-2.04) | 0.945 | 18 (49.0) | 0.78 (0.36-1.73) | 0.545 |
| GSTT1 | |||||||||
| Positive | 63 (72.0) | Reference | 48 (75.0) | Reference | 27 (73.0) | Reference | |||
| Negative | 24 (28.0) | 0.83 (0.41-1.67) | 0.596 | 16 (25.0) | 0.77 (0.35-1.70) | 0.513 | 10 (27.0) | 0.97 (0.40-2.38) | 0.947 |
| A313G GSTP1a | |||||||||
| AA | 46 (57.5) | Reference | 28 (50.0) | Reference | 22 (59.0) | Reference | |||
| AG/GG | 34 (42.5) | 0.89 (0.48-1.67) | 0.727 | 28 (50.0) | 1.47 (0.74-2.93) | 0.269 | 11 (41.0) | 0.66 (0.29-1.48) | 0.312 |
| C341T GSTP1b | |||||||||
| CC | 76 (90.5) | Reference | 57 (90.5) | Reference | 33 (91.6) | Reference | |||
| CT | 09 (9.5) | 1.07 (0.39-2.92) | 0.899 | 06 (9.5) | 0.48 (0.14-1.65) | 0.243 | 03 (8.4) | 1.44 (0.43-4.82) | 0.554 |
Odds Ratio (OR) adjusted for age, gender, smoking habit and alcohol consumption. aAmplification was possible for 80, 56 and 33 patients for oral cavity, larynx and pharynx, respectively. bAmplification was possible for 85, 63 and 36 patients for oral cavity, larynx and pharynx, respectively.